New Delhi: In a late-night affidavit, the central government on Sunday said that differential pricing of vaccines by the Center and states or private hospitals will have no effect on the citizens who will be given the vaccine free of cost.The Center said, "The price factor will not have any effect on the ultimate beneficiary, the eligible person is getting the vaccine as all the state governments have already declared their policy decision that each state will provide the vaccine to its residents, which will be  : Is the fee. "It said," due to consultation and 'persuasion' by both manufacturers of the vaccine, and have declared their respective values ​​which are the same for all state governments. It is pertinent to note that the central government has given its major vaccinations  By nature. The program, unlike state governments and / or private hospitals, places large purchase orders for vaccines and, therefore, has some reflections in the negotiated prices in this reality. "" Thus, while it is ensured that two  Vaccine manufacturers are not already affluent. Out of public funds, citizens should not make any payment to receive both doses of the vaccine, "the center said.  However, it also said that economics should take into account vaccine manufacturers.  "To date, only two vaccines are available from manufacturers. Both manufacturers [an Indian company and a second licensee of a British company] have taken financial risk in developing and manufacturing these vaccines and it is prudent to decide on pricing."  Through negotiation in a transparent consultation process taking into account the statutory provisions as a last resort in the present circumstances, ”it said.

 The central government said, "To ensure that there is no disparity between the states in the central government's active consultation with the two manufacturers, the central government has successfully set the same prices to be paid by all the state governments."

 "As per the policy, which is prepared keeping in mind the priority of the maximum vaccine to the citizens based on their vulnerability, to ensure equitable distribution of the vaccine quantity to all states at a uniform rate, the vaccine pricing decision in India  Possibility. Having an inevitable impact on efforts to bring more global vaccine manufacturers to India in the country, the policy mandates both manufacturers to supply 50% of the total manufactured volume of vaccine to the central government. The rationale behind this is that  Priority should be given in vaccination. For the most vulnerable group of the population. "Explaining the vaccine distribution formula, the Center said," All amounts are equally distributed among all states on a pro rata basis.  And is allocated to the states keeping in mind the total population of each state between the age group of 18- 44 years.] Out of 50%. The ota allotted to each state, divided by 50% - 50%.  In other words, out of the 50% allocated to the state, 50% will go to the state [18-44 and  Calculated on the basis of a supporter ratio based on the age group of the population] and the remaining 50% will go to the private sector on a contractual basis between the private sector and the vaccine manufacturers.